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Abstract
Neuropathic pain develops from a lesion or disease affecting the somatosensory system. Translational investigations
of neuropathic pain by using different animal models reveal that peripheral sensitization, spinal and cortical
plasticity may play critical roles in neuropathic pain. Furthermore, descending facilitatory or excitatory modulation
may also act to enhance chronic pain. Current clinical therapy for neuropathic pain includes the use of
pharmacological and nonpharmacological (psychological, physical, and surgical treatment) methods. However,
there is substantial need to better medicine for treating neuropathic pain. Future translational researchers and
clinicians will greatly facilitate the development of novel drugs for treating chronic pain including neuropathic
pain.
Introduction
Neuropathic pain develops from a lesion or disease
affecting the somatosensory system [1]. Triggers for
neuropathic pain are numerous and diverse. It can be
caused by direct and indirect injury to nerve systems.
The classification of neuropathic pain is often based on
the anatomical location of neurologic involvement (cen-
tral or peripheral). Major forms of clinical neuropathic
pain are given in Table 1. It is estimated that neuro-
pathic pain afflicts millions of people worldwide [2].
Neuropathic pain reduces the patients’ overall health-
related quality of life (sleep, mood, work, social and
recreational capacities), and generates health-care costs
several times higher than in control groups [3]. How-
ever, the management of patients with chronic neuro-
pathic pain is of utmost difficulty, and the response to
existing treatments is often inadequate. Therapy for
neuropathic pain includes the use of both pharmacologi-
cal and non-pharmacological (psychological, physical,
and surgical treatment) methods. The objectives of this
review are to outline the underlying mechanisms and
current therapies, and to discuss the recent advances
that should be useful to guide the treatment of neuro-
pathic pain in the future.
Neuropathic pain
According to the new definition by IASP, neuropathic pain
is a type of chronic pain caused by a lesion or disease of
the somatosensory nervous system. Lesion means the
directly damage to somatosensory system, while disease
refers to indirectly injury by metabolic stress, autoimmune
conditions or inflammatory and so on [1]. Such damage or
lesion can take place not only somatosensory nerves, but
also those innervating visceral organs. Hence, neuropathic
pain is an aberrant somatosensory processing that con-
trasts with the normal plasticity of somatosensory system
in nociceptive pain. According to the location of injury
sites, neuropathic pain can be further divided into central
neuropathic pain and peripheral neuropathic pain. Central
neuropathic pain is pain caused by a lesion or disease of
the central somatosensory nervous system; while periph-
eral neuropathic pain is caused by a lesion or disease of
the peripheral somatosensory nervous system. Despite the
different lesion or damage sites, central sensory synapses
are likely involved in both cases.
In order to distinguish from neuropathic pain, nocicep-
tive pain is also proposed by IASP to cover pain that arises
from actual or threatened damage to non-neural tissue
and is due to the activation of nociceptors. This new ter-
minology, however, is less used in present literature.
Basic mechanisms of neuropathic pain
Translational research involving animal models of neu-
ropathic pain aims to identify molecular targets for the
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recent studies employ chronic constriction injuries
[4,5], spared nerve ligation [6,7] or common peroneal
nerve ligation (CPN) [8,9], which include injury of, but
not severing of peripheral nerves. Nerve ligation mod-
els have served as powerful tools that not only mimic
clinical symptoms of chronic neuropathic pain, but
also result in robust molecular and cellular alterations.
For example, in humans chronic neuropathic pain is
manifested through spontaneous pain that can be
induced through innocuous stimuli (allodynia) [10].
Accordingly, mice and rats exposed to nerve ligation
surgery display reduced mechanical thresholds,
whereby previously innocuous mechanical stimuli elicit
nociceptive paw withdrawal responses after surgery
[11,12]. Similarly, chronic neuropathic pain patients
also display exaggerated responses to noxious stimuli
(hyperalgesia), and animal studies have shown similar
responses following peripheral nerve injury [13]. Sev-
eral tools have been devised to investigate these beha-
vioral effects, most notably Von Frey filaments for
mechanical allodynia, and the Hargreves test for ther-
mal hyperalgesia. In this manner, animal studies have
begun to identify molecular pathways that undergo
robust changes in correspondence with the develop-
ment of chronic neuropathic pain.
Through the use of animal models, various molecular
and cellular alterations have been identified in corre-
spondence with chronic neuropathic pain. At the per-
iphery, neuropathic injuries trigger sensitization and can
induce long-term abnormal neural activity along pri-
mary afferent pathways [14] (see Figure 1). In the spinal
cord, dorsal horn neurons display potentiated excitatory
responses and decreases in firing threshold in response
to chronic neuropathic pain [15-17]. For example, repe-
titive squeezing of the sciatic nerve induces long term
potentiation (LTP) at synapses of C-fibre [17], and
spinal activity has been found to be potentiated in
chronic pain settings, whereby previously sub-threshold
synaptic input is able to drive action potentials in dorsal
horn neurons [10]. Nevertheless, pharmacological inter-
ventions targeting spinal level alterations fail to ade-
quately terminate chronic pain, are often accompanied
by adverse side effects, and decrease in efficacy over
time. Consequently, recent investigations have focused
on molecular changes within brain regions that may
mediate chronic neuropathic pain. Interestingly, synaptic
plasticity within key cortical areas involved in pain has
been observed in correspondence with chronic neuro-
pathic pain [12]. Specifically, studies consistently provide
robust evidence of changes in excitatory transmission in
animal models of neuropathic pain. Within the anterior
cingulate cortex (ACC) for example, a critical brain
region involved in pain affect [18], intracellular signaling
cascades activated by peripheral neuropathic injury have
Table 1 Major forms of clinical neuropathic pain
Classification Example
Peripheral NP Postoperative neuralgia
Post-traumatic neuralgia
Incarcerated neuropathy (carpal tunnel syndrome)
Phantom limb pain
Painful polyneuropathy
Trigeminal neuralgia
Painful diabetic neuropathy
Nutritional deficiency-related neuropathy
Chemotherapy-induced neuropathy
Radicular neuropathy (cervical, thoracic or lumbar
vertebrae)
Postherpetic neuralgia
HIV neuropathy
Pain associated with Guillain-Barre’ syndrome
Idiopathic sensory neuropathy
Complex regional pain syndrome
Tumors caused by nerve compression and leakage
Central NP Post-stroke pain
Spinal cord injury pain
Spinal ischemia pain
Syringomyelia
Pain associated with multiple sclerosis
Parkinson’s disease-related pain
Table 2 Major animal models for the study of
neuropathic pain
Classification Name of model
Peripheral NP Neuroma model
Chronic constriction injury model (CCI)
Partial sciatic nerve ligation model (PSL or Seltzer
model)
L5/L6 spinal nerve ligation model (SNL)
Spared nerve injury
Sciatic cryoneurolysis model (SCN)
Inferior caudal trunk resection model (ICTR)
Sciatic inflammatory neuritis model (SIN)
Postherpetic neuralgia model (PHN)
Diabetic neuropathic pain model
Drugs-induced peripheral neuropathy model
Bone cancer pain models
HIV-induced neuropathy model
Trigeminal Neuralgia model
Orofacial pain model
Central NP Excitotoxic spinal cord injury (ESCI)
Photochemical SCI model
Weight-drop or contusive SCI (Allen’s Model)
Spinal hemisection
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potentiate glutamatergice x c i t a t o r yt r a n s m i s s i o n
[9,19,20]. For example, it was shown to induce phos-
phorylation of AMPA GluR1 channels and enhance
GluR1 mediated postsynaptic responses within the
mouse ACC after nerve injury [9]. Interestingly, cal-
cium-stimulated adenylyl cyclase 1 (AC1) was critical
for this effect. Accordingly, AC1 mediated protein
kinase M-ζ (PKMζ) activity was found to maintain neu-
ropathic pain induced alterations within the ACC [21].
Specifically, in vitro ACC slice recordings revealed that
ζ-pseudosubstrate inhibitory peptide (ZIP) inhibition of
PKMζ prevented synaptic potentiation induced by nerve
injury, whilst in vivo intra-ACC injections of ZIP signifi-
cantly reduced mechanical allodynia. These observations
allowed for the recent finding that specific inhibition of
AC1 reduces chronic pain in animal neuropathic pain
models [22]. Additional brain regions also have been
observed to undergo changes in excitatory transmission,
including the amygdala [23], insular cortex, and primary
and secondary sensory cortices [14].
Pharmacological management for neuropathic pain
The most effective clinical management to treat neuro-
pathic pain is pharmacological therapy. However, only 40-
60% of the patients achieve clinically meaningful pain
relief with pharmacotherapy, since some kinds of neuro-
pathic pain may be insensitive to ordinary analgesics. To
improve the current treatment of patients with neuro-
pathic pain, evidence-based studies should be made for
the pharmacological therapies that are used clinically.
Recently, numerous clinical researches have confirmed the
efficacy of antiepileptics, antidepressants, opioid analgesics,
and topical lidocaine [24] in some cases of neuropathic
pain. In addition, several novel drug treatments such as
botulinum toxin, capsaicin patch and lacosamide have
been also used for neuropathic pain therapy. Table 3 sum-
marizes the major pharmacological treatments for neuro-
pathic pain and their analgesia mechanisms.
Antiepileptics
Gabapentin and pregabalin are antiepileptics that have
been recommended as first-line drugs for neuropathic
Figure 1 Neuropathic pain is manifested through alterations at the peripheral, spinal, and cortical levels. At the periphery, neuropathic
pain is associated with changes in the excitability of nociceptors. At the spinal cord level, long-term potentiation (LTP) of sensory excitatory
synaptic transmission take place at least at similar time scales. The upregulation of postsynaptic AMPA receptors including possible recruitment
of silent synapses contribute to spinal LTP. Similar to LTP reported in other central synapses, different protein kinases and possible new protein
synthesis are also required. Within the cortex, neuropathic pain is associated with the induction of LTP including late-phase LTP (L-LTP) at cortical
synapses. Both presynaptic and postsynaptic alterations have been observed that result in ongoing potentiated excitatory activity. Dis-inhibition
of local inhibitory modulation have been also found within the spinal dorsal horn and cortical areas. Descending faciltiatory modulation from
cortical and sub-cortical areas are also thought to contribute to enhanced sensory transmission in the spinal cord dorsal horn.
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nit of calcium channels in various regions of the brain
a n dt h es u p e r f i c i a ls p i n a ld o r s a lh o r n .A sar e s u l t ,i t
inhibits the release of glutamate, norepinephrine, and
substance P [25]. Both drugs have been found to provide
effective pain relief in postherpetic neuralgia (PHN),
painful diabetic peripheral neuropathy (PDN) as well as
central pain [24]. Pregabalin and gabapentin have similar
advantage and disadvantage. They are well tolerated and
have no drug interactions. Dizziness and drowsiness are
their primary common adverse effects. The binding affi-
nity of pregabalin for the calcium channels a2-δ1 subu-
nit is 6 times greater than that of gabapentin, which
may explains why pregabalin is more clinically effective
at lower doses [26]. Due to short half-life, the adminis-
tration with gabapentin must be frequent. And careful
titration is required due to nonlinear absorption of
gabapentin [27]. Comparatively, pregabalin is well toler-
ated, and has predictable absorption across the gastroin-
testinal tract and linear pharmacokinetics [28].
Antidepressants
The beneficial effect of antidepressants has been estab-
lished in various neuropathic pain states. Tricyclic anti-
depressants (TCAs) and Selective serotonin
norepinephrine reuptake inhibitors (SSNRIs) are the
main antidepressants used in neuropathic pain treat-
ment. TCAs are efficacious for several types of neuro-
pathic pain including DPN, nerve injury pain, PHN, and
central poststroke pain [29]. Their analgesia effects are
attributed to inhibiting reuptake of serotonin and nora-
drenaline from presynaptic terminals. TCAs show both
analgesia efficacy and antidepressant effect, the pain-
relieving effect is independent of their mood-elevating
properties [30]. Therefore,T C A sm a yb eag o o dc h o i c e
for neuropathic pain patients with co-existing depres-
sion. Besides, TCAs are cheap and convenient to be
administered. TCAs have several side-effects (eg., dry
mouth, constipation, and orthostatichypotension), which
are mostly due to their anti-cholinergic and anti-hista-
minergic properties [29]. The notable side-effect is that
TCAs can also inhibit sodium channels to prolong car-
diotoxic QTc interval even with therapeutic doses, espe-
cially when patients suffer from ischemic cardiac disease
or ventricular conduction abnormalities. Therefore, an
ECG is mandatory before the start of the treatment [31].
SSNRIs such as duloxetine and venlafaxine have
shown consistent efficacy in DPN [32]. They selectively
inhibit reuptake of 5-HT and NE from presynaptic
membrane in the central nervous system. The advan-
tages of SSNRIs are the same as TCAs. SSNRIs are bet-
ter tolerated than TCAs since they do not show
anticholinergic, antihistaminic, and antiadrenergic side
effects [33]. The most common adverse effect is their
impact on gastrointestinal tract (eg., nausea and vomit-
ing) [24].
Topical lidocaine
Topical lidocaine has been demonstrated the efficacious
analgesic effect in patients with PHN and allodynia [24].
Despite its analgesia mechanisms is still unknown, it is
assumed to block sodium channels so that it can reduce
ectopic nociceptive pain signal transmission [34]. With-
out a relevant systemic absorption, topical application
offers a good benefit to risk ratio with mild local reac-
tions (eg., erythema or rash). Therefore, topical lidocaine
is particularly suitable for patients with localized periph-
eral neuropathic pain [24]. Currently, topical lidocaine
has not shown any efficacy in central neuropathic pain.
Opioid analgesics and tramadol
Several RCTs have demonstrated opioids to be effective
in relieving pain in PHN, DPN, spinal cord injury and
so on [24]. The analgesia effects of opioids are due to
inhibiting noxious transmission via μ, , δ receptors
Table 3 Major pharmacological treatment for
neuropathic pain and their basic mechanisms
Compound Mode of action
Antidepressants
Nortriptyline Inhibition of both serotonin and norepinephrine
reuptake
Desipramine Inhibition of both serotonin and norepinephrine
reuptake
Duloxetine Inhibition of both serotonin and norepinephrine
reuptake
Venlafaxine Inhibition of both serotonin and norepinephrine
reuptake
Anticonvulsants
Gabapentin Decreases release of glutamate, norepinephrine,
and substance P, with ligands on a2-δ subunit of
voltage
Pregabalin Decreases release of glutamate, norepinephrine,
and substance P, with ligands on a2-δ subunit of
voltage
Lacosamide Decreases release of presynaptic transmitters,
inhibition of voltage-gated sodium-channel.
Opioid agonists
Morphine μ-receptor agonism
Oxycodone μ-receptor agonism
Methadone μ-receptor agonism,-receptor antagonism
Levorphanol μ-receptor agonism
Tramadol μ-receptor agonism, inhibition of norepinephrine
and serotonin reuptake
Topical therapy
5% lidocaine
patch
Block of sodium channels
High-dose
capsaicin patch
Damage of nociceptive sensory axons, a highly
selective activating ligand for TRPV1,.
Botulinum toxin. Inhibition of both the exocytosis of acetylcholine
and some other neurotransmitters
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are not recommended as first-line treatments for
patients with neuropathic pain because the side-effects
(misuse, constipation, somnolence and drug addiction
and diversion) are difficult to be avoided. Clinicians
should address risk factors for abuse when patients need
to take opioids. In addition, opioids sometimes can
induce hyperalgesia, as pronocioceptive systems is also
activated after opioid exposure. Guidelines for chronic
noncancer pain indicate to use the lowest effective dose
of opioids, and to monitor the signs of misuse [36].
Tramadol, a synthetic opioid analogue, is a weak
analgesic through binding to the μ opioid receptor. And
it also performs analgesic effect by inhibiting serotonin
and norepinephrine reuptake. It could provide relatively
rapid pain relief in several neuropathic pain conditions
including PHN, DPN, and post-amputation pain [24]. Its
long-term side effects are similar to strong opioid
analgesics. Because of its action on serotonin, tramadol
can cause a serotonin syndrome when administrated
with serotoninergic drugs [24,37].
Nonpharmacological management for
neuropathic pain
Although pharmacotherapy remains the mainstay of
neuropathic pain management, application of medica-
tions alone always cannot achieve a sufficient level of
pain relief for the patients with neuropathic pain. There-
fore, when comprehensive analgesics fail to relieve pain
adequately even with maximum doses or side effects of
these medications undermine their analgesic effect,
other methods (psychological, physical, and surgical
treatment) are effective options to support and improve
pharmacological therapy. The major nonpharmacologi-
cal treatments for neuropathic pain are displayed in
Table 4.
Psychological treatment
Psychological treatment is also important, as neuro-
pathic pain commonly co-occurs with depression, anxi-
ety and poor quality of life [3]. Psychological
interventions attempt to change patients’ thoughts,
strengthen their beliefs and improve the aggressive
behavioral responses to pain. As a result, these comor-
bid conditions induced by neuropathic pain are removed
and persistent pain syndrome is relieved indirectly. Cog-
nitive and behavioral techniques, operant behavioral
therapy and self-hypnosis training are the primary
forms. The effectiveness of psychological managements
for neuropathic pain conditions has been proved in a
small preliminary study [38]. Basic mechanisms for neu-
ropathic pain triggered emotional and cognitive disor-
ders are unknown.
Physical treatment
Besides massages, electrophysiotherapy is the primary
technology of physical therapies that are also commonly
used for alternative pain-relieving treatment. One of the
simplest forms of electrophysiotherapy is TENS. A few
studies have demonstrated the efficacy of TENS [39].
Therefore, this technology is often used as an ancillary
support to the drug or other physical treatments.
Another is repetitive transcranial magnetic stimulation
(rTMS) which has showed transient efficacy in central
and peripheral neuropathic pains [40]. Acupuncture is a
kind of traditional medicine commonly used to relieve
pain and show to be effective in some cases of neuro-
pathic pain treatments [41]. However, much of basic
mechanisms for the analgesic effects induced by acu-
puncture remain to be investigated.
Surgical treatment
Neurosurgical interventions contain 2 categories such as
nerve ablation and neuromodulation. Ablative interven-
tions are always considered as last choice of treatment
because of the damage to the nervous system and mod-
est improvement. Recent studies using animal models
indicate that nerve injury may trigger long-term poten-
tiation in sensory synapses in the pain-related cortex
[19,42]. Comparatively, neuromodulation (peripheral
Table 4 Major nonpharmacological treatment of
neuropathic pain
Classification Name
Psychocorporal
treatment
Cognitive and behavioral techniques
Operant behavioral therapy
Self-hypnosis training
Physical treatment Massages
Joint mobilization
Transcutaneous electrical nerve stimulation
Repetitive transcranial magnetic
stimulation
Acupuncture
Neurosurgical techniques
Ablation Nerve avulsion or section
Dorsal rhizotomy
Spinal dorsal root entry zone lesions
Spinothalamic tractotomies
Thalamotomies
Cingulotomy
Frontal lobotomy
Destruction of the primary sensory cortex
Neuromodulation Periperal nerve stimulation
Spinal cord stimulation
Deep brain stimulation
Motor cortex stimulation
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stimulation and motor cortex stimulation) do not
damage nerve deliberately and is accepted by patients
gradually [39]. Spinal cord stimulation (SCS) is one of
the common treatments for refractory neuropathic pain
[39]. The therapy of SCS is based on the gate control
theory of pain, and its effects on pain perception are
also related to activation of inhibitory GABA-ergic and
cholinergic spinal interneurons [43]. Good evidence for
the pain relief effect of SCS has been found in failed
back surgery syndrome, complex regional pain syn-
drome, DPN and peripheral nerve injury [43]. The com-
m o ns i d ee f f e c t so fS C Sa r eh a r d w a r em a l f u n c t i o n m ,
wound infection, electrode migration and so on. Like-
wise, deep brain stimulation and motor cortex stimula-
tion are also invasive procedures that are showed to
alleviate chronic neuropathic pain [39]. One possible
mechanism for lost-effect of SCS in neurpathic pain
conditions is that many of endogenous inhibitory sys-
tems may be already activated in the condition of
chronic neuropathic pain, thus further stimulation will
not produce analgesic effects due to the occlusion.
Other therapeutic approaches and novel drug
targets
Botulinum toxin
Botulinum toxin (BTX), a neurotoxic protein is synthe-
sized by the bacterium Clostridium botulinum, and
there are seven different serotypes designated as A-G.
Animal experiments have confirmed that BTX-A can
inhibit the secretion of substance P and calcitonin gene-
related peptide in cultures of neurons, these results indi-
cate that BTX-A directly suppresses nociceptors which
may explain its relief of neuropathic pain symptoms
[44]. To assess the benefits of subcutaneous injection of
BTX-A for neuropathic pain treatment in clinical prac-
tice, several RCT studies have been performed to test
the therapeutic benefits. A clinical trial investigated the
analgesia effect of BTX-A in 29 patients with focal pain-
ful neuropathies and mechanical allodynia, and indicated
for the first time to confirm the analgesic efficiency of
BTX-A [45]. Recently, a RCT also confirmed the effect
of subcutaneous administration with BTX-A, it signifi-
cantly decreased pain, reduced opioid use compared
with lidocaine and placebo [46]. Although there are
some positive results for neuropathic pain treatment,
more RCTs with larger sample are needed to verify the
analgesic effect of BTX-A.
High-concentration capsaicin Patch
Capsaicin is a highly selective activating ligand for tran-
sient receptor potential vanilloid 1 receptor (TRPV1).
Interacting with sensory afferents via TRPV1, capsaicin
can cause local damage and defunctionalize nociceptive
sensory axons to transmit pain information [47]. Despite
low-concentration capsaicin is currently recommended
as third-line treatment of neuropathic pain, it is trouble-
some to be applied several times daily with limited effi-
ciency [24]. To avoid the discomfort application and
improve the potential therapeutic effect, high-concentra-
tion capsaicin patch (capsaicin, 8%) was developed to be
used in neuropathic pain treatment. 8% Capsaicin was
shown to provide rapid and sustain pain relief between
the second and the tenth week after the capsaicin appli-
cation in a RCT with 402 PHN patients [48]. In addi-
tion, application of high-concentration patch produced
significantly analgesia effect in patients with painful
HIV-associated distal sensory polyneuropathy [49].
Researches on long-term benefits of this treatment
found that repeated treatments with high-concentration
patch over 48 weeks are generally efficacious, safe and
well tolerated in PHN patients, with mild-to-moderate
application site erythema, pain, edema, and papules [50].
Epidermal nerve fiber density has shown nearly full
recovery 24 weeks after a high dose capsaicin exposure
in healthy volunteers [51]. However, this treatment is
unlikely to reduce any central potentiation triggered by
nerve injury.
Lacosamide
Lacosamide, synthesized as an anticonvulsive drug, also
show antinociceptive effects. It can control neuronal
hyperexcitability and modulate collapsin-response med-
iator protein 2 (CRMP-2) that inhibits a key modulator
of pain transmission N-methyl-D-aspartate receptor sub-
unit NR2B [43]. Several clinical trials have confirmed its
analgesia effect for painful DPN treatment [52]. Further-
more, long-term safety profile and sustained efficacy of
lacosamide have been demonstrated in an open-label
follow-on trial followed the DPN patients application of
lacosamide up to about 2.5 years [53].
Combination therapies
Clinically, two or more drugs are often used empirically
to achieve more satisfactory pain relief and fewer side
effects. However, there are only few studies of combina-
tion therapies to provide enough supportive evidence in
neuropathic pain treatment. Combination therapy with
gabapentin and extended-release morphine in patients
with PHN or painful DPN showed improved pain relief
with lower doses in comparison with either compound
was given alone [54]. The consistent results were also
verified by several other Clinical trials such as combina-
tion of gabapentin and extended release oxycodone [55],
pregabalin and oxycodone [56], pregabalin and topical
5% lidocaine [57], as well as sodium valproate and gly-
ceryl trinitrate spray [58]. Apart from combination of
two different drugs, combination therapies with
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achieved better analgesic efficacy. Results of a new study
about pregabalin and transcutaneous electrical nerve sti-
mulation (TENS) in combination showed a beneficial
effect than either alone for painful DPN treatment [59].
Conclusions and future direction of translational
research
Neuropathic pain, often caused by nerve injury, is com-
monly observed among patients with different diseases.
Development and maintenance of chronic neuropathic
pain are likely mediated by a series of complex molecu-
lar mechanisms. Previous attempts at identifying basic
pain mechanisms have focused mainly on neurons in
the DRG and spinal dorsal horn, and few synaptic-level
studies or new drugs are designed to target the injury-
related cortical plasticity that maintains chronic neuro-
pathic pain. As a result, few interventions that solely tar-
get neuropathic pain are limited. Recent efforts have
begun to strongly tackle cortical synaptic mechanisms
mediating neuropathic pain (for example, see Wang et
al., 2011 for AC1 as a potential novel target for neuro-
pathic pain), and promising therapeutic interventions
targeting cortical molecular mechanisms have begun to
emerge. Future research will likely explore specific intra-
cellular inhibitors of plasticity related targets, in contrast
to the plethora of nociception related medications cur-
rently available.
As a kind of complex diseases, it’s difficult to obtain
satisfactory analgesic results for neuropathic pain with
numerous pharmacological and non-pharmacological
therapies. Therefore, clinicians need to consider the
advantage and disadvantage of these managements to
avoid ineffective treatments, maximize curing proven
beneficial in clinical trials, and minimize the side effect
of therapies. To improve the current management of
patients with neuropathic pain, evidence-based basic
studies should be made for pharmacological or non-
pharmacological approaches to guide the managements
in the future.
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